Skip to content

Study · Non-randomized trial · n = 20 · 1975

4 results

Response of normal subjects to a single 2-milligram dose of glucagon administered intramuscularly.

Chernish SM, Davidson JA, Brunelle RL, Miller RE, Rosenak BD

Archives internationales de pharmacodynamie et de therapie1 Dec 1975Cited by 3 (Europe PMC)

PMID1212026 (opens in a new tab)PepBankPUB-01212026
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal subjects, glucagon increased WBC, bands, neutrophiles, fasting blood sugar, glucagon and insulin, and decreased lymphocytes.

    In plain wordsIn normal subjects, glucagon increased white blood cells, bands, neutrophils, fasting blood glucose, glucagon and insulin, and reduced lymphocytes.

    Peptide
    Glucagon
    Outcome
    MixedWhite blood cells, differential counts and metabolic hormones
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    After glucagon there was an increase in the WBC, bands, neutrophiles, fasting blood sugar, glucagon and insulin, and a decrease in the lymphocytes.
    1 context sentence
    Summary · context
    Twenty normal subjects received 2 mg of glucagon and placebo intramuscularly at daily intervals, double-blind and crossover.
  2. 02HumanNon-randomized trialSafety outcome

    In normal subjects, pulse rate did not change after glucagon.

    In plain wordsIn normal subjects, glucagon did not change pulse rate.

    Peptide
    Glucagon
    Outcome
    No significant changePulse rate
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    2 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    There was no change in the pulse rate or blood pressure with minimal reports of side effects.
    1 context sentence
    Summary · context
    Twenty normal subjects received 2 mg of glucagon and placebo intramuscularly at daily intervals, double-blind and crossover.
  3. 03HumanNon-randomized trialSafety outcome

    In normal subjects, blood pressure did not change after glucagon.

    In plain wordsIn normal subjects, glucagon did not change blood pressure.

    Peptide
    Glucagon
    Outcome
    No significant changeBlood pressure
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    There was no change in the pulse rate or blood pressure with minimal reports of side effects.
    1 context sentence
    Summary · context
    Twenty normal subjects received 2 mg of glucagon and placebo intramuscularly at daily intervals, double-blind and crossover.
  4. 04HumanNon-randomized trialSafety outcome

    In normal subjects, glucagon produced few, mild and transient side effects, not much greater than placebo.

    In plain wordsIn normal subjects, glucagon caused few, mild and temporary side effects, not much greater than placebo.

    Peptide
    Glucagon
    Outcome
    Direction not reportedReported side effects
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Glucagon is remarkably safe and produces few, mild and transient side effects, not much greater than placebo.
    2 context sentences
    Summary · context
    There was no change in the pulse rate or blood pressure with minimal reports of side effects.
    Summary · context
    Twenty normal subjects received 2 mg of glucagon and placebo intramuscularly at daily intervals, double-blind and crossover.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.